Assel Talaspayeva is a Boston, Massachusetts based female Ophthalmologist who is specialized in Ophthalmology. Active license number of Assel Talaspayeva is KZ03VBM01388151 for Ophthalmology in . Assel Talaspayeva is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Assel Talaspayeva speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
MD
Gender:
Female
Practice Address:
1 Joslin Pl, Boston, Massachusetts, 02215-5306
Phone:
617-309-2400
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1053027839
NPI Enumeration Date:
25 Jan, 2023
NPI Last Update On:
25 Jan, 2023
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Assel Talaspayeva are as mentioned below.
License Number
Specialization
State
Status
KZ03VBM01388151
Ophthalmology
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
111 Wadsworth Ave Apt 21f, New York, New York
Zip:
10033-6118
Phone Number:
917-815-9779
Fax Number:
--
Patients can reach Assel Talaspayeva at 1 Joslin Pl, Boston, Massachusetts or can call to book an appointment on 617-309-2400. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.